Publish Time: 2022-12-14 Origin: 迪飞医学
Recently, the National Health and Health Commission Clinical Laboratory Center (NCCL) (hereinafter referred to as 'Clinical Inspection Center') announced the 2022 EB virus nucleic acid detection, cytomegalovirus nucleic acid detection and national clinical laboratory PCR detection (non-virus) second. Subcompartmental quality assessment results.Nanjing Difei Medical Testing Laboratory and Beijing Shihe Medical Testing Laboratory actively participated, and all passed with full marks!
Full marks!Nanjing Difei EB Virus Nucleic Acid Detection External Quality Assessment
Full marks!External Quality Assessment of Beijing Shihe EB Virus Nucleic Acid Detection
Full marks!External Quality Assessment of Nanjing DIFI CMV Nucleic Acid Detection
Full marks!Beijing Shihe cytomegalovirus nucleic acid detection external quality assessment
Full marks!Nanjing Difei PCR assay (non-virus) external quality assessment
Full marks!Beijing Shihe PCR assay (non-virus) external quality assessment
Passed the second external quality assessment of EB virus nucleic acid detection, cytomegalovirus nucleic acid detection and national clinical laboratory PCR determination (non-virus) in 2022 with full marks, which fully verified that Datafei Medical Laboratory has EB virus, cytomegalovirus, cytomegalovirus, The PCR detection capability of pathogenic bacteria such as Mycobacterium tuberculosis, Chlamydia trachomatis and Neisseria gonorrhoeae is also the full recognition of the technical strength and high-quality level of Difei Medical in the field of microbial PCR detection by the National Clinical Inspection Center.Difei Medical has the advantages of a molecular diagnosis platform with leading technology, standardized management, strict quality control, and reliable results. Its infectious pathogen detection products are cost-effective, high-sensitivity, and high-accurate, helping the precise diagnosis of infectious pathogens.